Therapeutics News and Research

RSS

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.

18 Apr 2013

Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.

18 Apr 2013

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Mast Therapeutics, Inc. today announced that two posters for its lead product candidate, MST-188, were presented at the 7th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.

18 Apr 2013

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid Drug Platform.

18 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

Researchers find potential new genetic chemotherapy approach for cancer treatment

Researchers at The Jackson Laboratory have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment that could significantly reduce side effects and the development of treatment resistance compared with traditional chemotherapy.

18 Apr 2013

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to clinical trial results.

18 Apr 2013

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee.

18 Apr 2013

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death.

17 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France.

16 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.

16 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Bioactive plasma-based biomaterials can accelerate tissue healing

Platelet-rich plasma derived from blood contains growth factors and other bioactive molecules that promote healing at sites of tissue injury. However, it is difficult to deliver and retain these molecules at a target site, and clinical results have proven to be mixed - until now.

16 Apr 2013

Research roundup: Lesson for insurance exchanges from Europe; Health care disparities among Hispanics

As states and the federal government begin creating insurance exchanges under the health law, researchers highlight several lessons from Switzerland and the Netherlands.

15 Apr 2013

Pharmacological study shows interactions between drugs can be detected with minute doses

Clinical pharmacologists at Heidelberg University Hospital have achieved major progress for improving the reliability of drugs. In a pharmacological study, they showed for the first time that interactions between drugs can be detected with minute doses in the range of nanograms.

15 Apr 2013

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge. A novel nanoparticle-based approach that enables more efficient delivery of siRNA drugs is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

12 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

Australian, Singapore researchers join hands to combat disease-causing bugs

The fight against a number of significant infectious diseases in the Asia-Pacific region has been given a boost through a new research collaboration between the National Health and Medical Research Council in Australia and the Agency for Science, Technology and Research in Singapore.

12 Apr 2013

Therapeutics News and Research

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Mast Therapeutics' data show that MST-188 reduces aggregation of both older and younger RBC

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

Researchers find potential new genetic chemotherapy approach for cancer treatment

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Bioactive plasma-based biomaterials can accelerate tissue healing

Research roundup: Lesson for insurance exchanges from Europe; Health care disparities among Hispanics

Pharmacological study shows interactions between drugs can be detected with minute doses

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Australian, Singapore researchers join hands to combat disease-causing bugs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News